Full Press Release Details
SAN FRANCISCO , April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR ) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022 , at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through May 27, 2022 .
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S); (970) 315-0453 (international) Conference ID: 5888057 (Nektar Therapeutics is the host)
About Nektar Therapeutics Nektar Therapeutics is a biopharmaceutical company developing investigational medicines in oncology, immunology, and inflammatory diseases. The company also has a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .